New combo therapy shows promise for Tough-to-Treat lymphomas
NCT ID NCT03015896
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether combining two drugs—nivolumab (a monoclonal antibody) and lenalidomide (a chemotherapy-like drug)—can safely and effectively treat people with non-Hodgkin or Hodgkin lymphoma that has returned or is not responding to treatment. The study involves 36 participants and aims to find the best dose and assess side effects. If the combination works, it could provide a new option for patients with few alternatives.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nivolumab (Opdivo) and lenalidomide (Revlimid)
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with lymphoma that has returned or stopped responding to standard therapies.
- What could go wrong
- This is an early-phase trial with only 36 participants, so results may not apply broadly. The combination may cause significant side effects, and it is not yet known if it works better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRADE 3A FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory University
Atlanta, Georgia, 30322, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Can two immune boosters outsmart follicular lymphoma without chemo?
- Can a Two-Pronged antibody boost chemo against tough lymphomas?
- Can pressurized oxygen boost cord blood transplants?
- Triple-Drug cocktail aims to boost remission in follicular lymphoma
- Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?